Sangamo Therapeutics Inc (SGMO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.14 (-4.40%), Market cap $0.07B, 52-week low–high $0.10 ~ $0.74.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clini
Financial statements, price targets, institutional (13F) holdings and related news for Sangamo Therapeutics Inc are updated in real time on BlackAll Trade.
Sangamo Therapeutics Inc trades at $0.14 (-4.40%). Real-time quotes and charts are available on BlackAll Trade.
Sangamo Therapeutics Inc has a market cap of about $0.07B.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases i